Physician profile
Alok Kumar
NPI 1154403962
$3,044.66
in general payments reported to CMS, 2019-2025
30 companies · $594 in 2025
The $594 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $222 · 2021: $380 · 2022: $341 · 2023: $342 · 2024: $889 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.34 |
| Education | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $749.71 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $369.90 | 2022-2025 | |
| Abbvie INC. | $339.90 | 2019-2023 | |
| Exeltis, USA INC. | $171.64 | 2019-2025 | Slynd |
| Teva Pharmaceuticals USA, INC. | $168.63 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $145.09 | 2019-2022 | |
| Hologic Sales and Service, LLC | $135.24 | 2021-2025 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $105.48 | 2019-2025 | |
| Coopersurgical, INC. | $98.54 | 2020-2025 | Paragard T 380a, Sos |
| Shield Therapeutics INC | $91.64 | 2023-2025 | Accrufer |
| Biogen, INC. | $77.62 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $66.96 | 2023-2025 | Injectafer |
| Avanos Medical | $55.69 | 2019 | |
| Agile Therapeutics, INC. | $53.99 | 2021-2022 | |
| Avion Pharmaceuticals | $53.97 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $52.26 | 2019-2022 | |
| Therapeuticsmd, INC. | $51.84 | 2019-2021 | |
| Organon LLC | $44.47 | 2024-2025 | Jada System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.35 | 2019-2020 | |
| Evofem Biosciences, INC. | $28.32 | 2021 | |
| Lupin INC. | $26.19 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $19.68 | 2024 | Myfembree |
| Solventum Corporation | $17.97 | 2024 | Prevena |
| Pfizer INC. | $14.22 | 2025 | |
| Myovant Sciences INC. | $13.79 | 2022 | |
| Millicent US INC | $13.66 | 2025 | Femlyv, Intrarosa |
| Virtus Pharmaceuticals LLC | $13.59 | 2021 | |
| Glaxosmithkline, LLC. | $13.29 | 2021 | |
| Merck Sharp & Dohme LLC | $12.93 | 2019 | |
| Channel Medsystems, INC. | $5.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.